Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
Cell ; 153(3): 666-77, 2013 Apr 25.
Article in English | MEDLINE | ID: mdl-23622249

ABSTRACT

The analysis of exonic DNA from prostate cancers has identified recurrently mutated genes, but the spectrum of genome-wide alterations has not been profiled extensively in this disease. We sequenced the genomes of 57 prostate tumors and matched normal tissues to characterize somatic alterations and to study how they accumulate during oncogenesis and progression. By modeling the genesis of genomic rearrangements, we identified abundant DNA translocations and deletions that arise in a highly interdependent manner. This phenomenon, which we term "chromoplexy," frequently accounts for the dysregulation of prostate cancer genes and appears to disrupt multiple cancer genes coordinately. Our modeling suggests that chromoplexy may induce considerable genomic derangement over relatively few events in prostate cancer and other neoplasms, supporting a model of punctuated cancer evolution. By characterizing the clonal hierarchy of genomic lesions in prostate tumors, we charted a path of oncogenic events along which chromoplexy may drive prostate carcinogenesis.


Subject(s)
Chromosome Aberrations , Gene Expression Regulation, Neoplastic , Genome, Human , Prostatic Neoplasms/genetics , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Cohort Studies , Genome-Wide Association Study , Humans , Male , Neuroendocrine Tumors/genetics , Neuroendocrine Tumors/pathology , Prostatic Neoplasms/pathology
2.
Cell ; 150(2): 251-63, 2012 Jul 20.
Article in English | MEDLINE | ID: mdl-22817889

ABSTRACT

Despite recent insights into melanoma genetics, systematic surveys for driver mutations are challenged by an abundance of passenger mutations caused by carcinogenic UV light exposure. We developed a permutation-based framework to address this challenge, employing mutation data from intronic sequences to control for passenger mutational load on a per gene basis. Analysis of large-scale melanoma exome data by this approach discovered six novel melanoma genes (PPP6C, RAC1, SNX31, TACC1, STK19, and ARID2), three of which-RAC1, PPP6C, and STK19-harbored recurrent and potentially targetable mutations. Integration with chromosomal copy number data contextualized the landscape of driver mutations, providing oncogenic insights in BRAF- and NRAS-driven melanoma as well as those without known NRAS/BRAF mutations. The landscape also clarified a mutational basis for RB and p53 pathway deregulation in this malignancy. Finally, the spectrum of driver mutations provided unequivocal genomic evidence for a direct mutagenic role of UV light in melanoma pathogenesis.


Subject(s)
Genome-Wide Association Study , Melanoma/genetics , Mutagenesis , Ultraviolet Rays , Amino Acid Sequence , Cells, Cultured , Exome , Humans , Melanocytes/metabolism , Models, Molecular , Molecular Sequence Data , Proto-Oncogene Proteins B-raf/genetics , Sequence Alignment , rac1 GTP-Binding Protein/genetics
3.
Nature ; 499(7457): 214-218, 2013 Jul 11.
Article in English | MEDLINE | ID: mdl-23770567

ABSTRACT

Major international projects are underway that are aimed at creating a comprehensive catalogue of all the genes responsible for the initiation and progression of cancer. These studies involve the sequencing of matched tumour-normal samples followed by mathematical analysis to identify those genes in which mutations occur more frequently than expected by random chance. Here we describe a fundamental problem with cancer genome studies: as the sample size increases, the list of putatively significant genes produced by current analytical methods burgeons into the hundreds. The list includes many implausible genes (such as those encoding olfactory receptors and the muscle protein titin), suggesting extensive false-positive findings that overshadow true driver events. We show that this problem stems largely from mutational heterogeneity and provide a novel analytical methodology, MutSigCV, for resolving the problem. We apply MutSigCV to exome sequences from 3,083 tumour-normal pairs and discover extraordinary variation in mutation frequency and spectrum within cancer types, which sheds light on mutational processes and disease aetiology, and in mutation frequency across the genome, which is strongly correlated with DNA replication timing and also with transcriptional activity. By incorporating mutational heterogeneity into the analyses, MutSigCV is able to eliminate most of the apparent artefactual findings and enable the identification of genes truly associated with cancer.


Subject(s)
Genetic Heterogeneity , Mutation/genetics , Neoplasms/genetics , Oncogenes/genetics , Artifacts , DNA Replication Timing , Exome/genetics , False Positive Reactions , Gene Expression , Genome, Human/genetics , Humans , Lung Neoplasms/genetics , Mutation Rate , Neoplasms/classification , Neoplasms/pathology , Neoplasms, Squamous Cell/genetics , Reproducibility of Results , Sample Size
4.
Nature ; 488(7409): 106-10, 2012 Aug 02.
Article in English | MEDLINE | ID: mdl-22820256

ABSTRACT

Medulloblastomas are the most common malignant brain tumours in children. Identifying and understanding the genetic events that drive these tumours is critical for the development of more effective diagnostic, prognostic and therapeutic strategies. Recently, our group and others described distinct molecular subtypes of medulloblastoma on the basis of transcriptional and copy number profiles. Here we use whole-exome hybrid capture and deep sequencing to identify somatic mutations across the coding regions of 92 primary medulloblastoma/normal pairs. Overall, medulloblastomas have low mutation rates consistent with other paediatric tumours, with a median of 0.35 non-silent mutations per megabase. We identified twelve genes mutated at statistically significant frequencies, including previously known mutated genes in medulloblastoma such as CTNNB1, PTCH1, MLL2, SMARCA4 and TP53. Recurrent somatic mutations were newly identified in an RNA helicase gene, DDX3X, often concurrent with CTNNB1 mutations, and in the nuclear co-repressor (N-CoR) complex genes GPS2, BCOR and LDB1. We show that mutant DDX3X potentiates transactivation of a TCF promoter and enhances cell viability in combination with mutant, but not wild-type, ß-catenin. Together, our study reveals the alteration of WNT, hedgehog, histone methyltransferase and now N-CoR pathways across medulloblastomas and within specific subtypes of this disease, and nominates the RNA helicase DDX3X as a component of pathogenic ß-catenin signalling in medulloblastoma.


Subject(s)
Cerebellar Neoplasms/genetics , Exome/genetics , Genome, Human/genetics , Medulloblastoma/genetics , Mutation/genetics , Cerebellar Neoplasms/classification , Child , DEAD-box RNA Helicases/chemistry , DEAD-box RNA Helicases/genetics , DEAD-box RNA Helicases/metabolism , DNA Helicases/chemistry , DNA Helicases/genetics , DNA-Binding Proteins/genetics , Hedgehog Proteins/metabolism , Histone Methyltransferases , Histone-Lysine N-Methyltransferase/genetics , Histone-Lysine N-Methyltransferase/metabolism , Humans , Intracellular Signaling Peptides and Proteins/genetics , LIM Domain Proteins/genetics , Medulloblastoma/classification , Models, Molecular , Neoplasm Proteins/genetics , Nuclear Proteins/chemistry , Nuclear Proteins/genetics , Patched Receptors , Patched-1 Receptor , Promoter Regions, Genetic/genetics , Protein Structure, Tertiary/genetics , Proto-Oncogene Proteins/genetics , Receptors, Cell Surface/genetics , Repressor Proteins/genetics , Signal Transduction , TCF Transcription Factors/metabolism , Transcription Factors/chemistry , Transcription Factors/genetics , Tumor Suppressor Protein p53/genetics , Wnt Proteins/metabolism , beta Catenin/genetics , beta Catenin/metabolism
5.
Nature ; 485(7399): 502-6, 2012 May 09.
Article in English | MEDLINE | ID: mdl-22622578

ABSTRACT

Melanoma is notable for its metastatic propensity, lethality in the advanced setting and association with ultraviolet exposure early in life. To obtain a comprehensive genomic view of melanoma in humans, we sequenced the genomes of 25 metastatic melanomas and matched germline DNA. A wide range of point mutation rates was observed: lowest in melanomas whose primaries arose on non-ultraviolet-exposed hairless skin of the extremities (3 and 14 per megabase (Mb) of genome), intermediate in those originating from hair-bearing skin of the trunk (5-55 per Mb), and highest in a patient with a documented history of chronic sun exposure (111 per Mb). Analysis of whole-genome sequence data identified PREX2 (phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2)--a PTEN-interacting protein and negative regulator of PTEN in breast cancer--as a significantly mutated gene with a mutation frequency of approximately 14% in an independent extension cohort of 107 human melanomas. PREX2 mutations are biologically relevant, as ectopic expression of mutant PREX2 accelerated tumour formation of immortalized human melanocytes in vivo. Thus, whole-genome sequencing of human melanoma tumours revealed genomic evidence of ultraviolet pathogenesis and discovered a new recurrently mutated gene in melanoma.


Subject(s)
Genome, Human/genetics , Guanine Nucleotide Exchange Factors/genetics , Melanoma/genetics , Mutation/genetics , Sunlight/adverse effects , Chromosome Breakpoints/radiation effects , DNA Damage , DNA Mutational Analysis , Gene Expression Regulation, Neoplastic , Guanine Nucleotide Exchange Factors/metabolism , Humans , Melanocytes/metabolism , Melanocytes/pathology , Melanoma/pathology , Mutagenesis/radiation effects , Mutation/radiation effects , Oncogenes/genetics , Ultraviolet Rays/adverse effects
6.
Nature ; 486(7403): 405-9, 2012 Jun 20.
Article in English | MEDLINE | ID: mdl-22722202

ABSTRACT

Breast carcinoma is the leading cause of cancer-related mortality in women worldwide, with an estimated 1.38 million new cases and 458,000 deaths in 2008 alone. This malignancy represents a heterogeneous group of tumours with characteristic molecular features, prognosis and responses to available therapy. Recurrent somatic alterations in breast cancer have been described, including mutations and copy number alterations, notably ERBB2 amplifications, the first successful therapy target defined by a genomic aberration. Previous DNA sequencing studies of breast cancer genomes have revealed additional candidate mutations and gene rearrangements. Here we report the whole-exome sequences of DNA from 103 human breast cancers of diverse subtypes from patients in Mexico and Vietnam compared to matched-normal DNA, together with whole-genome sequences of 22 breast cancer/normal pairs. Beyond confirming recurrent somatic mutations in PIK3CA, TP53, AKT1, GATA3 and MAP3K1, we discovered recurrent mutations in the CBFB transcription factor gene and deletions of its partner RUNX1. Furthermore, we have identified a recurrent MAGI3-AKT3 fusion enriched in triple-negative breast cancer lacking oestrogen and progesterone receptors and ERBB2 expression. The MAGI3-AKT3 fusion leads to constitutive activation of AKT kinase, which is abolished by treatment with an ATP-competitive AKT small-molecule inhibitor.


Subject(s)
Breast Neoplasms/classification , Breast Neoplasms/genetics , Mutation/genetics , Translocation, Genetic/genetics , Algorithms , Breast Neoplasms/pathology , Core Binding Factor Alpha 2 Subunit/genetics , Core Binding Factor beta Subunit/genetics , DNA Mutational Analysis , Exome/genetics , Female , Gene Fusion/genetics , Humans , Membrane Proteins/genetics , Mexico , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , Vietnam
7.
Nature ; 470(7333): 214-20, 2011 Feb 10.
Article in English | MEDLINE | ID: mdl-21307934

ABSTRACT

Prostate cancer is the second most common cause of male cancer deaths in the United States. However, the full range of prostate cancer genomic alterations is incompletely characterized. Here we present the complete sequence of seven primary human prostate cancers and their paired normal counterparts. Several tumours contained complex chains of balanced (that is, 'copy-neutral') rearrangements that occurred within or adjacent to known cancer genes. Rearrangement breakpoints were enriched near open chromatin, androgen receptor and ERG DNA binding sites in the setting of the ETS gene fusion TMPRSS2-ERG, but inversely correlated with these regions in tumours lacking ETS fusions. This observation suggests a link between chromatin or transcriptional regulation and the genesis of genomic aberrations. Three tumours contained rearrangements that disrupted CADM2, and four harboured events disrupting either PTEN (unbalanced events), a prostate tumour suppressor, or MAGI2 (balanced events), a PTEN interacting protein not previously implicated in prostate tumorigenesis. Thus, genomic rearrangements may arise from transcriptional or chromatin aberrancies and engage prostate tumorigenic mechanisms.


Subject(s)
Genome, Human/genetics , Prostatic Neoplasms/genetics , Adaptor Proteins, Signal Transducing , Carrier Proteins/genetics , Case-Control Studies , Cell Adhesion Molecules/genetics , Chromatin/genetics , Chromatin/metabolism , Chromosome Aberrations , Chromosome Breakpoints , Epigenesis, Genetic/genetics , Gene Expression Regulation, Neoplastic , Guanylate Kinases , Humans , Male , PTEN Phosphohydrolase/genetics , PTEN Phosphohydrolase/metabolism , Recombination, Genetic/genetics , Signal Transduction/genetics , Transcription, Genetic
8.
Nature ; 471(7339): 467-72, 2011 Mar 24.
Article in English | MEDLINE | ID: mdl-21430775

ABSTRACT

Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis is poorly understood. Here we report the massively parallel sequencing of 38 tumour genomes and their comparison to matched normal DNAs. Several new and unexpected oncogenic mechanisms were suggested by the pattern of somatic mutation across the data set. These include the mutation of genes involved in protein translation (seen in nearly half of the patients), genes involved in histone methylation, and genes involved in blood coagulation. In addition, a broader than anticipated role of NF-κB signalling was indicated by mutations in 11 members of the NF-κB pathway. Of potential immediate clinical relevance, activating mutations of the kinase BRAF were observed in 4% of patients, suggesting the evaluation of BRAF inhibitors in multiple myeloma clinical trials. These results indicate that cancer genome sequencing of large collections of samples will yield new insights into cancer not anticipated by existing knowledge.


Subject(s)
Genome, Human/genetics , Multiple Myeloma/genetics , Mutation/genetics , Amino Acid Sequence , Blood Coagulation/genetics , CpG Islands/genetics , DNA Mutational Analysis , DNA Repair/genetics , Exons/genetics , Exosome Multienzyme Ribonuclease Complex , Genomics , Histones/metabolism , Homeodomain Proteins/genetics , Homeostasis/genetics , Humans , Methylation , Models, Molecular , Molecular Sequence Data , Multiple Myeloma/drug therapy , Multiple Myeloma/enzymology , Multiple Myeloma/metabolism , NF-kappa B/metabolism , Oncogenes/genetics , Open Reading Frames/genetics , Protein Biosynthesis/genetics , Protein Conformation , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Proto-Oncogene Proteins B-raf/genetics , Proto-Oncogene Proteins B-raf/metabolism , RNA Processing, Post-Transcriptional/genetics , Ribonucleases/chemistry , Ribonucleases/genetics , Signal Transduction/genetics , Transcription, Genetic/genetics
9.
Hum Mutat ; 36(4): E2423-9, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25703262

ABSTRACT

Oncotator is a tool for annotating genomic point mutations and short nucleotide insertions/deletions (indels) with variant- and gene-centric information relevant to cancer researchers. This information is drawn from 14 different publicly available resources that have been pooled and indexed, and we provide an extensible framework to add additional data sources. Annotations linked to variants range from basic information, such as gene names and functional classification (e.g. missense), to cancer-specific data from resources such as the Catalogue of Somatic Mutations in Cancer (COSMIC), the Cancer Gene Census, and The Cancer Genome Atlas (TCGA). For local use, Oncotator is freely available as a python module hosted on Github (https://github.com/broadinstitute/oncotator). Furthermore, Oncotator is also available as a web service and web application at http://www.broadinstitute.org/oncotator/.


Subject(s)
Databases, Genetic , Neoplasms/genetics , Computational Biology/methods , Genetic Variation , Genomics/methods , Humans , Internet , Neoplasms/diagnosis , Neoplasms/metabolism , Web Browser
10.
Nature ; 450(7171): 893-8, 2007 Dec 06.
Article in English | MEDLINE | ID: mdl-17982442

ABSTRACT

Somatic alterations in cellular DNA underlie almost all human cancers. The prospect of targeted therapies and the development of high-resolution, genome-wide approaches are now spurring systematic efforts to characterize cancer genomes. Here we report a large-scale project to characterize copy-number alterations in primary lung adenocarcinomas. By analysis of a large collection of tumours (n = 371) using dense single nucleotide polymorphism arrays, we identify a total of 57 significantly recurrent events. We find that 26 of 39 autosomal chromosome arms show consistent large-scale copy-number gain or loss, of which only a handful have been linked to a specific gene. We also identify 31 recurrent focal events, including 24 amplifications and 7 homozygous deletions. Only six of these focal events are currently associated with known mutations in lung carcinomas. The most common event, amplification of chromosome 14q13.3, is found in approximately 12% of samples. On the basis of genomic and functional analyses, we identify NKX2-1 (NK2 homeobox 1, also called TITF1), which lies in the minimal 14q13.3 amplification interval and encodes a lineage-specific transcription factor, as a novel candidate proto-oncogene involved in a significant fraction of lung adenocarcinomas. More generally, our results indicate that many of the genes that are involved in lung adenocarcinoma remain to be discovered.


Subject(s)
Adenocarcinoma/genetics , Genome, Human/genetics , Lung Neoplasms/genetics , Neoplasms/genetics , Cell Line, Tumor , Chromosome Deletion , Chromosomes, Human, Pair 14/genetics , Gene Amplification/genetics , Genomics , Genotype , Humans , Intracellular Signaling Peptides and Proteins/genetics , Loss of Heterozygosity/genetics , Nuclear Proteins/genetics , Polymorphism, Single Nucleotide/genetics , Proto-Oncogene Mas , RNA Interference , Thyroid Nuclear Factor 1 , Transcription Factors/genetics
11.
Proc Natl Acad Sci U S A ; 105(25): 8713-7, 2008 Jun 24.
Article in English | MEDLINE | ID: mdl-18552176

ABSTRACT

Oncogenic activation of tyrosine kinases is a common mechanism of carcinogenesis and, given the druggable nature of these enzymes, an attractive target for anticancer therapy. Here, we show that somatic mutations of the fibroblast growth factor receptor 2 (FGFR2) tyrosine kinase gene, FGFR2, are present in 12% of endometrial carcinomas, with additional instances found in lung squamous cell carcinoma and cervical carcinoma. These FGFR2 mutations, many of which are identical to mutations associated with congenital craniofacial developmental disorders, are constitutively activated and oncogenic when ectopically expressed in NIH 3T3 cells. Inhibition of FGFR2 kinase activity in endometrial carcinoma cell lines bearing such FGFR2 mutations inhibits transformation and survival, implicating FGFR2 as a novel therapeutic target in endometrial carcinoma.


Subject(s)
Carcinoma/genetics , Endometrial Neoplasms/genetics , Mutation , Receptor, Fibroblast Growth Factor, Type 2/genetics , Animals , Carcinoma/drug therapy , Carcinoma/metabolism , Cell Line, Tumor , Cell Proliferation , Cell Survival , Endometrial Neoplasms/drug therapy , Endometrial Neoplasms/metabolism , Female , Mice , NIH 3T3 Cells , Receptor, Fibroblast Growth Factor, Type 2/antagonists & inhibitors , Receptor, Fibroblast Growth Factor, Type 2/metabolism , Transfection
12.
J Vis Exp ; (106): e52879, 2015 Dec 09.
Article in English | MEDLINE | ID: mdl-26710000

ABSTRACT

Although targeted therapies are initially effective, resistance inevitably emerges. Several methods, such as genetic analysis of resistant clinical specimens, have been applied to uncover these resistance mechanisms to facilitate follow-up care. Although these approaches have led to clinically relevant discoveries, difficulties in attaining the relevant patient material or in deconvoluting the genomic data collected from these specimens have severely hampered the path towards a cure. To this end, we here describe a tool for expeditious discovery that may guide improvement in first-line therapies and alternative clinical management strategies. By coupling preclinical in vitro or in vivo drug selection with next-generation sequencing, it is possible to identify genomic structural variations and/or gene expression alterations that may serve as functional drivers of resistance. This approach facilitates the spontaneous emergence of alterations, enhancing the probability that these mechanisms may be observed in the patients. In this protocol we provide guidelines to maximize the potential for uncovering single nucleotide variants that drive resistance using adherent lines.


Subject(s)
Drug Resistance/genetics , High-Throughput Nucleotide Sequencing/methods , Antineoplastic Agents/pharmacology , Drug Resistance, Neoplasm/genetics , HCT116 Cells , Humans , In Vitro Techniques , Molecular Targeted Therapy
13.
ACS Chem Biol ; 9(10): 2247-54, 2014 Oct 17.
Article in English | MEDLINE | ID: mdl-25058389

ABSTRACT

The small-molecule probes STF-31 and its analogue compound 146 were discovered while searching for compounds that kill VHL-deficient renal cell carcinoma cell lines selectively and have been reported to act via direct inhibition of the glucose transporter GLUT1. We profiled the sensitivity of 679 cancer cell lines to STF-31 and found that the pattern of response is tightly correlated with sensitivity to three different inhibitors of nicotinamide phosphoribosyltransferase (NAMPT). We also performed whole-exome next-generation sequencing of compound 146-resistant HCT116 clones and identified a recurrent NAMPT-H191R mutation. Ectopic expression of NAMPT-H191R conferred resistance to both STF-31 and compound 146 in cell lines. We further demonstrated that both STF-31 and compound 146 inhibit the enzymatic activity of NAMPT in a biochemical assay in vitro. Together, our cancer-cell profiling and genomic approaches identify NAMPT inhibition as a critical mechanism by which STF-31-like compounds inhibit cancer cells.


Subject(s)
Cell Survival/drug effects , Cytokines/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Neoplasms/drug therapy , Nicotinamide Phosphoribosyltransferase/antagonists & inhibitors , Small Molecule Libraries/pharmacology , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Blotting, Western , Cytokines/genetics , Cytokines/metabolism , Drug Resistance, Neoplasm/drug effects , Enzyme Inhibitors/chemistry , Gene Expression Profiling , High-Throughput Nucleotide Sequencing/methods , Humans , Molecular Structure , Mutation/genetics , Neoplasms/enzymology , Neoplasms/pathology , Nicotinamide Phosphoribosyltransferase/genetics , Nicotinamide Phosphoribosyltransferase/metabolism , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Small Molecule Libraries/chemistry , Tumor Cells, Cultured
14.
Nat Genet ; 45(5): 478-86, 2013 May.
Article in English | MEDLINE | ID: mdl-23525077

ABSTRACT

The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years. With a 5-year survival rate of ~15%, the identification of new therapeutic targets for EAC is greatly important. We analyze the mutation spectra from whole-exome sequencing of 149 EAC tumor-normal pairs, 15 of which have also been subjected to whole-genome sequencing. We identify a mutational signature defined by a high prevalence of A>C transversions at AA dinucleotides. Statistical analysis of exome data identified 26 significantly mutated genes. Of these genes, five (TP53, CDKN2A, SMAD4, ARID1A and PIK3CA) have previously been implicated in EAC. The new significantly mutated genes include chromatin-modifying factors and candidate contributors SPG20, TLR4, ELMO1 and DOCK2. Functional analyses of EAC-derived mutations in ELMO1 identifies increased cellular invasion. Therefore, we suggest the potential activation of the RAC1 pathway as a contributor to EAC tumorigenesis.


Subject(s)
Adenocarcinoma/genetics , Biomarkers, Tumor/genetics , Esophageal Neoplasms/genetics , Exome/genetics , Genome, Human/genetics , Mutation/genetics , Chromosome Mapping , Gene Rearrangement , High-Throughput Nucleotide Sequencing , Humans , Neoplasm Invasiveness
15.
Nat Genet ; 45(3): 279-84, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23334666

ABSTRACT

Neuroblastoma is a malignancy of the developing sympathetic nervous system that often presents with widespread metastatic disease, resulting in survival rates of less than 50%. To determine the spectrum of somatic mutation in high-risk neuroblastoma, we studied 240 affected individuals (cases) using a combination of whole-exome, genome and transcriptome sequencing as part of the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative. Here we report a low median exonic mutation frequency of 0.60 per Mb (0.48 nonsilent) and notably few recurrently mutated genes in these tumors. Genes with significant somatic mutation frequencies included ALK (9.2% of cases), PTPN11 (2.9%), ATRX (2.5%, and an additional 7.1% had focal deletions), MYCN (1.7%, causing a recurrent p.Pro44Leu alteration) and NRAS (0.83%). Rare, potentially pathogenic germline variants were significantly enriched in ALK, CHEK2, PINK1 and BARD1. The relative paucity of recurrent somatic mutations in neuroblastoma challenges current therapeutic strategies that rely on frequently altered oncogenic drivers.


Subject(s)
Exome , Mutation , Neuroblastoma , Cell Line, Tumor , Genetic Predisposition to Disease , Genome, Human , Humans , Neuroblastoma/genetics , Neuroblastoma/physiopathology , Polymorphism, Single Nucleotide , Sequence Analysis, DNA , Transcriptome
16.
Nat Genet ; 45(12): 1483-6, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24185511

ABSTRACT

The diagnosed incidence of small intestine neuroendocrine tumors (SI-NETs) is increasing, and the underlying genomic mechanisms have not yet been defined. Using exome- and genome-sequence analysis of SI-NETs, we identified recurrent somatic mutations and deletions in CDKN1B, the cyclin-dependent kinase inhibitor gene, which encodes p27. We observed frameshift mutations of CDKN1B in 14 of 180 SI-NETs, and we detected hemizygous deletions encompassing CDKN1B in 7 out of 50 SI-NETs, nominating p27 as a tumor suppressor and implicating cell cycle dysregulation in the etiology of SI-NETs.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p27/genetics , Intestinal Neoplasms/genetics , Mutation , Neuroendocrine Tumors/genetics , Cell Cycle/genetics , Cohort Studies , Genes, Tumor Suppressor , Genetic Predisposition to Disease , Humans , Intestinal Neoplasms/epidemiology , Intestinal Neoplasms/pathology , Intestine, Small/pathology , Neuroendocrine Tumors/epidemiology , Neuroendocrine Tumors/pathology , Sequence Analysis, DNA
17.
Cancer Res ; 72(17): 4383-93, 2012 Sep 01.
Article in English | MEDLINE | ID: mdl-22751462

ABSTRACT

A more detailed understanding of the somatic genetic events that drive gastrointestinal adenocarcinomas is necessary to improve diagnosis and therapy. Using data from high-density genomic profiling arrays, we conducted an analysis of somatic copy-number aberrations in 486 gastrointestinal adenocarcinomas including 296 esophageal and gastric cancers. Focal amplifications were substantially more prevalent in gastric/esophageal adenocarcinomas than colorectal tumors. We identified 64 regions of significant recurrent amplification and deletion, some shared and others unique to the adenocarcinoma types examined. Amplified genes were noted in 37% of gastric/esophageal tumors, including in therapeutically targetable kinases such as ERBB2, FGFR1, FGFR2, EGFR, and MET, suggesting the potential use of genomic amplifications as biomarkers to guide therapy of gastric and esophageal cancers where targeted therapeutics have been less developed compared with colorectal cancers. Amplified loci implicated genes with known involvement in carcinogenesis but also pointed to regions harboring potentially novel cancer genes, including a recurrent deletion found in 15% of esophageal tumors where the Runt transcription factor subunit RUNX1 was implicated, including by functional experiments in tissue culture. Together, our results defined genomic features that were common and distinct to various gut-derived adenocarcinomas, potentially informing novel opportunities for targeted therapeutic interventions.


Subject(s)
Adenocarcinoma/genetics , Cell Transformation, Neoplastic/genetics , Gastrointestinal Neoplasms/genetics , Genomic Instability , Cell Line, Tumor , Chromosome Aberrations , Cluster Analysis , Colonic Neoplasms/genetics , Core Binding Factor Alpha 2 Subunit/genetics , DNA Copy Number Variations , Esophageal Neoplasms/genetics , Gene Deletion , Genomics , Humans , Stomach Neoplasms/genetics
18.
Nat Genet ; 44(6): 685-9, 2012 May 20.
Article in English | MEDLINE | ID: mdl-22610119

ABSTRACT

Prostate cancer is the second most common cancer in men worldwide and causes over 250,000 deaths each year. Overtreatment of indolent disease also results in significant morbidity. Common genetic alterations in prostate cancer include losses of NKX3.1 (8p21) and PTEN (10q23), gains of AR (the androgen receptor gene) and fusion of ETS family transcription factor genes with androgen-responsive promoters. Recurrent somatic base-pair substitutions are believed to be less contributory in prostate tumorigenesis but have not been systematically analyzed in large cohorts. Here, we sequenced the exomes of 112 prostate tumor and normal tissue pairs. New recurrent mutations were identified in multiple genes, including MED12 and FOXA1. SPOP was the most frequently mutated gene, with mutations involving the SPOP substrate-binding cleft in 6-15% of tumors across multiple independent cohorts. Prostate cancers with mutant SPOP lacked ETS family gene rearrangements and showed a distinct pattern of genomic alterations. Thus, SPOP mutations may define a new molecular subtype of prostate cancer.


Subject(s)
Hepatocyte Nuclear Factor 3-alpha/genetics , Mediator Complex/genetics , Microtubule-Associated Proteins/genetics , Mutation , Prostatic Neoplasms/genetics , Exome , Humans , Male , Sequence Analysis, DNA
19.
PLoS One ; 6(6): e20351, 2011.
Article in English | MEDLINE | ID: mdl-21666749

ABSTRACT

BACKGROUND: Squamous cell lung carcinomas account for approximately 25% of new lung carcinoma cases and 40,000 deaths per year in the United States. Although there are multiple genomically targeted therapies for lung adenocarcinoma, none has yet been reported in squamous cell lung carcinoma. METHODOLOGY/PRINCIPAL FINDINGS: Using SNP array analysis, we found that a region of chromosome segment 8p11-12 containing three genes-WHSC1L1, LETM2, and FGFR1-is amplified in 3% of lung adenocarcinomas and 21% of squamous cell lung carcinomas. Furthermore, we demonstrated that a non-small cell lung carcinoma cell line harboring focal amplification of FGFR1 is dependent on FGFR1 activity for cell growth, as treatment of this cell line either with FGFR1-specific shRNAs or with FGFR small molecule enzymatic inhibitors leads to cell growth inhibition. CONCLUSIONS/SIGNIFICANCE: These studies show that FGFR1 amplification is common in squamous cell lung cancer, and that FGFR1 may represent a promising therapeutic target in non-small cell lung cancer.


Subject(s)
Carcinoma, Non-Small-Cell Lung/enzymology , Carcinoma, Non-Small-Cell Lung/genetics , Gene Amplification , Lung Neoplasms/enzymology , Lung Neoplasms/genetics , Receptor, Fibroblast Growth Factor, Type 1/antagonists & inhibitors , 3' Untranslated Regions/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Gene Amplification/drug effects , Gene Knockdown Techniques , Genetic Loci/genetics , Humans , Lung Neoplasms/pathology , Open Reading Frames/genetics , Protein Kinase Inhibitors/pharmacology , RNA, Small Interfering/metabolism , Receptor, Fibroblast Growth Factor, Type 1/metabolism
20.
Science ; 333(6046): 1157-60, 2011 Aug 26.
Article in English | MEDLINE | ID: mdl-21798893

ABSTRACT

Head and neck squamous cell carcinoma (HNSCC) is a common, morbid, and frequently lethal malignancy. To uncover its mutational spectrum, we analyzed whole-exome sequencing data from 74 tumor-normal pairs. The majority exhibited a mutational profile consistent with tobacco exposure; human papillomavirus was detectable by sequencing DNA from infected tumors. In addition to identifying previously known HNSCC genes (TP53, CDKN2A, PTEN, PIK3CA, and HRAS), our analysis revealed many genes not previously implicated in this malignancy. At least 30% of cases harbored mutations in genes that regulate squamous differentiation (for example, NOTCH1, IRF6, and TP63), implicating its dysregulation as a major driver of HNSCC carcinogenesis. More generally, the results indicate the ability of large-scale sequencing to reveal fundamental tumorigenic mechanisms.


Subject(s)
Carcinoma/genetics , Head and Neck Neoplasms/genetics , Mutation , Neoplasms, Squamous Cell/genetics , Receptor, Notch1/genetics , Sequence Analysis, DNA , Algorithms , Apoptosis , Carcinoma/metabolism , Carcinoma/virology , Carcinoma, Squamous Cell , Cell Differentiation , Exons , Head and Neck Neoplasms/metabolism , Head and Neck Neoplasms/virology , Humans , Neoplasms, Squamous Cell/metabolism , Neoplasms, Squamous Cell/virology , Papillomaviridae/isolation & purification , Papillomavirus Infections/virology , Point Mutation , Receptor, Notch1/metabolism , Sequence Deletion , Signal Transduction , Smoking , Squamous Cell Carcinoma of Head and Neck , Nicotiana
SELECTION OF CITATIONS
SEARCH DETAIL